Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model

Epidemiological studies indicate that women have a higher risk of Alzheimer's disease (AD) even after adjustment for age. Though transgenic mouse models of AD develop AD-related amyloid beta (Abeta) and/or tau pathology, gender differences have not been well documented in these models. In this study, we found that female 3xTg-AD transgenic mice expressing mutant APP, presenilin-1 and tau have significantly more aggressive Abeta pathology. We also found an increase in beta-secretase activity and a reduction of neprilysin in female mice compared to males; this suggests that a combination of increased Abeta production and decreased Abeta degradation may contribute to higher risk of AD in females. In contrast to significantly more aggressive Abeta pathology in females, gender did not affect the levels of phosphorylated tau in 3xTg-AD mice. These results point to the involvement of Abeta pathways in the higher risk of AD in women. In addition to comparison of pathology between genders at 9, 16 and 23 months of age, we examined the progression of Abeta pathology at additional age points; i.e., brain Abeta load, intraneuronal oligomeric Abeta distribution and plaque load, in male 3xTg-AD mice at 3, 6, 9, 12, 16, 20 and 23 months of age. These findings confirm progressive Abeta pathology in 3xTg-AD transgenic mice, and provide guidance for their use in therapeutic research.

[1]  E. Bigio,et al.  Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.

[2]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[3]  Wen-Lang Lin,et al.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.

[4]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[5]  C. Masters,et al.  Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease , 2002 .

[6]  P. Davies,et al.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. L. François,et al.  Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease , 2001, Neuroscience.

[8]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[9]  Jason Eriksen,et al.  A decade of modeling Alzheimer's disease in transgenic mice. , 2006, Trends in genetics : TIG.

[10]  J. Trojanowski,et al.  Epitopes that span the tau molecule are shared with paired helical filaments , 1988, Neuron.

[11]  L. Hersh,et al.  Estrogen regulates neprilysin activity in rat brain , 2004, Neuroscience Letters.

[12]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[13]  F. Bian,et al.  Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. , 2001, The American journal of pathology.

[14]  T. Saido,et al.  Region‐specific reduction of Aβ‐degrading endopeptidase, neprilysin, in mouse hippocampus upon aging , 2002, Journal of neuroscience research.

[15]  F. LaFerla,et al.  Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. , 2007, The American journal of pathology.

[16]  B. Hyman,et al.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.

[17]  S. Paul,et al.  Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease. , 2005, Endocrinology.

[18]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[19]  K. Ashe,et al.  Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.

[20]  B L Miller,et al.  Estrogen for Alzheimer’s disease in women , 2000, Neurology.

[21]  D. Selkoe,et al.  The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.

[22]  P. Aisen,et al.  Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. , 2004, Biochemical and biophysical research communications.

[23]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[24]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[25]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[26]  E. Mandelkow,et al.  The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region. , 1992, The EMBO journal.

[27]  David W. Smith,et al.  Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[28]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[29]  P. Wong,et al.  BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild‐type mice 2 , 2006, Journal of neurochemistry.

[30]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.

[31]  J. Lafrancois,et al.  Modulation of Aβ peptides by estrogen in mouse models , 2002, Journal of neurochemistry.

[32]  L. Hy,et al.  Prevalence of AD among whites , 2000, Neurology.

[33]  J. Ávila,et al.  Estradiol Prevents Neural Tau Hyperphosphorylation Characteristic of Alzheimer's Disease , 2005, Annals of the New York Academy of Sciences.

[34]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[35]  J. Trojanowski,et al.  Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  N. Takata,et al.  Hippocampal synthesis of estrogens and androgens which are paracrine modulators of synaptic plasticity: Synaptocrinology , 2006, Neuroscience.

[37]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[38]  P. Aisen,et al.  A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[39]  I. McDowell,et al.  Alzheimer’s disease: Insights from epidemiology , 2001, Aging.

[40]  Miles W. Miller,et al.  Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice , 1999, Nature Medicine.

[41]  B. Hyman,et al.  The Neuropathological Diagnosis of Alzheimer’s Disease: Clinical-Pathological Studies , 1997, Neurobiology of Aging.

[42]  R. Berry,et al.  β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis , 2007, The Journal of Neuroscience.

[43]  Ilana S. Hairston,et al.  Environmental Enrichment Reduces Aβ Levels and Amyloid Deposition in Transgenic Mice , 2005, Cell.

[44]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[45]  Brenda L Plassman,et al.  Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.

[46]  H C Liu,et al.  Effects of estrogen on cognition, mood, and cerebral blood flow in AD , 2000, Neurology.

[47]  R. Nelson,et al.  Anesthesia Leads to Tau Hyperphosphorylation through Inhibition of Phosphatase Activity by Hypothermia , 2007, The Journal of Neuroscience.

[48]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[49]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[50]  M. Higuchi,et al.  Metabolism of amyloid-β peptide and Alzheimer's disease , 2005 .

[51]  G. Lindwall,et al.  Phosphorylation affects the ability of tau protein to promote microtubule assembly. , 1984, The Journal of biological chemistry.

[52]  C. Lemere,et al.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.

[53]  S. Gandy,et al.  Post-menopausal estrogen deprivation and Alzheimer's disease , 2000, Experimental Gerontology.

[54]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[55]  E G Tangalos,et al.  Postmenopausal estrogen replacement therapy and risk of AD , 1999, Neurology.

[56]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[57]  Yama Akbari,et al.  Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders , 2005, Neurobiology of Aging.

[58]  M. Mattson,et al.  Deglycosylated anti‐amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration , 2007, The European journal of neuroscience.

[59]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.